Boehringer and MD Anderson extend KRAS cancer collaboration

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center have extended and expanded a collaboration exploring medicines targeting lung cancer with KRAS mutations. 

Trial answers the KRAS question for Keytruda in lung cancer

6 Ways To Finally Drug RAS Oncogenes

Are You Developing Effective Anti-RAS Therapeutics?

Boehringer Ingelheim to present data at RAS Summit Europe

RAS- Targeted Drug Discovery Europe Conference